NCT05656235 - Renal Retention in High Grade Upper Tract Urothelial Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 25, 2024

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2029

Conditions

High Grade Urothelial CarcinomaBladder CancerUrothelial Carcinoma Bladder

Interventions

DRUG

Enfortumab vedotin

Enfortumab vedotin 1.25mg/kg on Days 1 and 8 every 3 weeks for up to 35 weeks (each cycle = 21 days)

DRUG

Pembrolizumab

Pembrolizumab 200mg on Day 1 every 3 weeks for up to 35 weeks (each cycle = 21 days)

Trial Locations (2)

RECRUITING

Johns Hopkins University: Sibley Memorial Hospital, Washington D.C.

RECRUITING

Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center, Baltimore